Kirkland-Led AbbVie To Pay $8.7B For Cerevel Therapeutics
By Al Barbarino · December 6, 2023, 7:12 PM EST
Kirkland & Ellis LLP-advised AbbVie Inc. said Wednesday it has agreed to buy Latham & Watkins LLP-guided Cerevel Therapeutics and its neuroscience treatment portfolio for approximately $8.7 billion....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login